Renal biopsy can be extremely valuable in the management of patients with l
upus nephritis. It is remarkably common to find pathological evidence of su
bstantial nephron loss in patients with low-grade laboratory abnormalities.
This is due to compensatory hypertrophy and hemodynamic adjustments within
the less-diseased nephron mass. It has been shown that the decision to ins
titute immunosuppressive therapy is highly informed by the results of renal
biopsy and offers the prospect of achieving more favorable renal outcomes.
Kidney biopsies should be evaluated by dedicated renal pathology services
experienced in diagnostic light, immunofluorescence and electron microscopy
. Biopsies should be classified according to the World Health Organization
(WHO) system and specific lesions semiquantitatively scored against a check
list of features comprising activity (reversible) and chronicity (irreversi
ble damage) indices. The renal biopsy findings should be reviewed jointly b
y pathologists and the clinicians caring for patients with lupus nephritis.